V
44
8
CL
58
2
PSA
50
-3
APH
56
-2
GILD
47
-2
SEE
55
5
MDT
60
-3
ALL
53
-4
CRM
59
-5
DE
45
-3
LOW
62
4
VIX
35
-5
MAC
62
2
DGX
36
-3
CME
45
-3
WDC
66
3
MET
60
2
DRI
50
3
REGN
53
-3
PYPL
52
3
V
44
8
CL
58
2
PSA
50
-3
APH
56
-2
GILD
47
-2
SEE
55
5
MDT
60
-3
ALL
53
-4
CRM
59
-5
DE
45
-3
LOW
62
4
VIX
35
-5
MAC
62
2
DGX
36
-3
CME
45
-3
WDC
66
3
MET
60
2
DRI
50
3
REGN
53
-3
PYPL
52
3
Financhill
Back

Dianthus Therapeutics, Inc. 10K Form

Buy
61

DNTH
Dianthus Therapeutics, Inc.

Last Price:
$44.26
Seasonality Move:
24.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DNTH News And Ratings

See the #1 stock for the next 7 days that we like better than DNTH

DNTH Financial Statistics

Sales & Book Value

Annual Sales: $6.2M
Cash Flow: $-30.6M
Price / Cash Flow: 0
Annual Sales: $12.75
Price / Book: 3.47

Profitability

EPS (TTM): -3.49200
Net Income (TTM): $-126.3M
Gross Margin: $5.8M
Return on Equity: -33.81%
Return on Assets: -31.9%

Dianthus Therapeutics, Inc. Earnings Forecast

Key Dianthus Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 9 years for DNTH is 93.39%.
  • The Selling, General & Administrative Expenses for DNTH have been equal to 400.87% of Gross Profit Margin.
  • The Research & Development expenses have been 1,332.88% of Revenue.
  • The Net Earning history of DNTH is -1,362.77% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 5 years.

Dianthus Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DNTH
Website: dianthustx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 17.35
Quick Ratio: 17.09

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DNTH Technical Analysis vs Fundamental Analysis

Buy
61
Dianthus Therapeutics, Inc. (DNTH) is a Buy

Is Dianthus Therapeutics, Inc. a Buy or a Sell?